Neuropathologies associated with dideoxycytosine: a preliminary assessment.
Morse
D E
DE
Food and Drug Administration, Rockville, Maryland 20857.
Evoniuk
G
G
Black
P L
PL
Ussery
M A
MA
D000161:Acoustic Stimulation; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D004285:Dogs; D004327:Drinking Behavior / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D000882:Haplorhini; D007942:Leukemia, Experimental / Q000188:drug therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009043:Motor Activity / Q000187:drug effects*; D009498:Neurotoxins / Q000633:toxicity*; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D011925:Rauscher Virus; D013216:Reflex, Startle / Q000187:drug effects*; D016047:Zalcitabine / Q000633:toxicity*
D000998:Antiviral Agents; D009498:Neurotoxins; D016047:Zalcitabine